NationwideFirst Patients in Canada Imaged with Illuccix(R): Now Commercially Available Nationwide Canada NewsWire MELBOURNE, Australia, May 1, 2023 MELBOURNE, Australia, May 1, 2023 /CNW/ -- Telix Pharmaceuticals Limited (ASX: TLX,Telix, the Company) today announces first patients have been imaged in Canada with itscommercially available prostate cancer imaging agent, Illuccix(R) [kit for thepreparation of gallium ((68) Ga) PSMA-11 for intravenous injection]. With Illuccix now available nationwide in Canada through Telix's partner IsologicInnovative Radiopharmaceuticals (Isologic), INITIO Medical Group in Burnaby, BC (INITIO)became one of the first sites to administer this novel PSMA-PET imaging agent that canhelp healthcare professionals diagnose the stage and spread of prostate cancer -- animportant step for men with this disease. Illuccix, after radiolabeling with gallium ((68) Ga), is indicated for use withpositron emission tomography (PET) of prostate specific membrane antigen (PSMA) positivelesions in men with prostate cancer: -- with suspected metastasis who are suitable for initial definitive therapy; -- with suspected recurrence with elevated serum prostate specific antigen (PSA) level.
TLX Chart, page-495
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.47 |
Change
0.130(0.56%) |
Mkt cap ! $7.855B | |||
| Open | High | Low | Value | Volume |
| $23.82 | $23.99 | $23.23 | $28.94M | 1.231M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2801 | $23.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.50 | 7000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |